Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A Duval
BRCA1/2-Mutated Breast Cancer in Select EU Markets: Incidence, Treatable Populations, and Potential Market Size for Parp Inhibitors
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Frequent Alteration of DNA Damage Signalling and Repair Pathways in Human Colorectal Cancers With Microsatellite Instability
Oncogene
Cancer Research
Genetics
Molecular Biology
Related publications
PARP Inhibitors for BRCA1/2-mutated and Sporadic Ovarian Cancer: Current Practice and Future Directions
British Journal of Cancer
Cancer Research
Oncology
More Breast Cancer Patients Could Benefit From PARP Inhibitors
Cancer
Cancer Research
Oncology
Synthetic Lethality Exploitation by an Anti–Trop-2-Sn-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –Wild-Type Triple-Negative Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Inhibitors Targeting CDK4/6, PARP and PI3K in Breast Cancer: A Review
Therapeutic Advances in Medical Oncology
Oncology
PARP Inhibitors in Ovarian Cancer
Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer
The PARP Inhibitor AZD2281 (Olaparib) Induces Autophagy/Mitophagy in BRCA1 and BRCA2 Mutant Breast Cancer Cells
International Journal of Oncology
Cancer Research
Oncology
Comparative Oncogenomics Identifies Combinations of Driver Genes and Drug Targets in BRCA1-mutated Breast Cancer
Nature Communications
Astronomy
Genetics
Molecular Biology
Biochemistry
Chemistry
Physics
Hereditary Breast Cancer in Moroccan Populations: BRCA1 & BRCA2 at the Glance
Journal of Genetic Syndromes & Gene Therapy
